Research articles
ScienceAsia 51 (2023): 1-9 |doi:
10.2306/scienceasia1513-1874.2023.022
Vasculo-protective effect of human serum albumin
nanoparticles encapsulated recombinant human secretory
leukocyte protease inhibitor (rhSLPI-HSA-NPs) against
ischemia/reperfusion injury in vascular endothelial cells
Chayanisa Phutiyothin, Faprathan Pikwong, Wannapat Chouyratchakarn, Phornsawat Baipaywad,
Sarawut Kumphune*
ABSTRACT: The reduction of vascular endothelial cell injury may potentially contribute to the preservation of
cardiomyocytes from ischemia/reperfusion (I/R) injury. Previous investigations have shown that secretory leukocyte
protease inhibitors (SLPI) have the potential to reduce I/R-induced cardiac cells and vascular endothelial cell injury.
Nonetheless, the short half-life of SLPI and its susceptibility to degradation by circulating enzymes limit its potential for
therapeutic applications. In this study, we employed human serum albumin (HSA) nanoparticles (NPs) to encapsulate
recombinant human SLPI (rhSLPI) protein. Subsequently, we investigated the effect of these rhSLPI-encapsulated-HSA
NPs (rhSLPI-HSA-NPs) on vascular endothelial cells that had been exposed to simulated ischemia/reperfusion (sI/R)
injury in an in vitro experimental model. For the physical properties of HSA-NPs and rhSLPI-HSA-NPs, the average
sizes, the polydispersity index (PDI) values, and the zeta potentials of the two NPs were 131.7 nm and 250.2 nm,
0.5 and 0.6, and ?15.27 and ?13.83 mV, respectively. Furthermore, the rhSLPI-HSA-NPs inhibited the trypsin activity
without causing toxicity to human vascular endothelial cells (EA.hy926). The results showed that pre-treatment with
1 ?g/ml and 10 ?g/ml rhSLPI-HSA-NPs could significantly reduce sI/R and induce vascular endothelial cell death and
injury. In summary, the current study demonstrated for the first time the vasculoprotective effect of rhSLPI-HSA-NPs in
decreasing vascular endothelial cell damage generated by an in vitro simulated ischemia/reperfusion.
Download PDF
1 Downloads 125 Views
| a |
Biomedical Engineering Institute (BMEI), Chiang Mai University, Chiang Mai 50200 Thailand |
* Corresponding author, E-mail: sarawut.kumphune@cmu.ac.th
Received 10 Oct 2023, Accepted 26 Dec 2024
|
